免疫检查点抑制剂诱导的心肌炎:综合性综述与临床病例见解
María José Santa-Ana-Bayona1, Camila Ponce-Acosta1, Edgar Quispe-Silvestre2
1Facultad Mexicana de Medicina, Universidad La Salle, Ciudad de México, México. Universidad La Salle Facultad Mexicana de Medicina Universidad La Salle Ciudad de México Peru.
Archivos peruanos de cardiologia y cirugia cardiovascular
|November 20, 2025
概括
免疫检查点抑制剂 (ICI) 提供癌症治疗的好处,但可以导致危及生命的心肌炎. 早期检测和干预对于管理这种罕见的心血管毒性至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了癌症治疗,改善了各种癌症患者的生存率.
- 然而,ICI可以引发与免疫相关的不良事件,特别是严重的心血管毒性,如心肌炎.
研究的目的:
- 综合审查ICI诱导心肌炎的机制,临床表现,诊断和管理.
- 突出早期检测和及时干预对于管理这种不良事件的关键需求.
主要方法:
- 本综述综合了关于ICI诱导心肌炎的当前文献.
- 它探讨了潜在的免疫机制和临床表现.
- 讨论了诊断挑战和治疗策略.
主要成果:
- ICI诱导的心肌炎是癌症免疫治疗的罕见但严重的并发症.
- 早期识别和管理是改善患者结果的关键.
- 需要进一步的研究来优化治疗和降低风险.
结论:
- 由ICI诱导的心肌炎需要谨慎监测和多学科的方法.
- 了解它的病理生理学对于开发有针对性的疗法至关重要.
- 与心血管安全平衡癌症治疗疗效至关重要.
相关概念视频
Myocarditis III: Medical Management
165
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
165
Myocarditis II: Clinical Features and Diagnostic Tests
242
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
242
Myocarditis I: Introduction
347
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
347
Myocarditis IV: Nursing Management
197
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
197
Pericarditis III: Medical Management
290
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
290
Cardiomyopathy I: Introduction and Classification
483
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
483


